Literature DB >> 16429316

Fixing the conformations of diamineplatinum(II)-GpG chelates: NMR and CD signatures of individual rotamers.

Diana Over1, Gildas Bertho, Miguel-Angel Elizondo-Riojas, Jirí Kozelka.   

Abstract

The bulky, asymmetric analog of the antitumor drug cisplatin, [PtCl(2)(tmen)] (tmen = N,N,N'-trimethylethylenediamine), was used to produce crosslinks with the dinucleotide d(GpG), modeling the most frequent lesions that cisplatin and its analogs cause to DNA. The ligand tmen was chosen because it is expected to constrain the guanine cis to the NMe(2) group in the adduct [Pt(tmen){d(GpG)}](+) to an orientation perpendicular to the coordination plane and to stabilize the other guanine in an oblique orientation, thus maintaining a head-to-head geometry typical of cisplatin-d(GpG) crosslinks within single- and double-stranded DNA. Of the four possible combinations of tmen chirality (R or S symmetry of the coordinated NHMe group) and crosslink direction (5'-G bound cis to the secondary or the tertiary amino group of tmen), two isomers were preponderantly formed, [Pt(R-tmen){d(GpG)}](+) with 5'-G bound cis to NMe(2) and [Pt(S-tmen){d(GpG)}](+) with 5'-G bound cis to NHMe. The former was shown to have a right-handed R2 orientation of guanines similar to that found in duplex DNA, whereas the latter had a left-handed L1 orientation that modeled cisplatin-d(GpG) adducts within single-stranded DNA. The R2 rotamer was found to be in an equilibrium (as observed using EXSY spectroscopy) with a minor fraction (< or =4%) of a Delta-HT rotamer related to R2 by rotation of the 3'-G about the Pt-N7 bond. The major rotamers R2 and L1 were isolated using reverse-phase HPLC, and their NMR and CD signatures were compared to those of the corresponding rotamers of the less hindered adduct [Pt(dmen)(GpG)](+) (dmen = N,N-dimethylethylenediamine). From this and other comparisons with previously reported platinum dinucleotide complexes, and from molecular modeling, it could be concluded that both steric repulsion between guanine and substituents of the cis amino group and N-H...O6 hydrogen bonding are significant effects favoring the oblique orientation of one guanine base typical of the HH rotamers of [Pt(diamine){d(GpG)}](+) and [Pt(diamine)(GpG)](+) complexes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429316     DOI: 10.1007/s00775-005-0058-5

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  16 in total

1.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

Authors:  E R Jamieson; S J Lippard
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Unrestrained 5 ns molecular dynamics simulation of a cisplatin-DNA 1,2-GG adduct provides a rationale for the NMR features and reveals increased conformational flexibility at the platinum binding site.

Authors:  M A Elizondo-Riojas; J Kozelka
Journal:  J Mol Biol       Date:  2001-12-14       Impact factor: 5.469

3.  Imprinting structural information from a GpG ligand into the configuration of a chiral diamine ligand through second-sphere communication in platinum(II) complexes.

Authors:  K M Williams; T Scarcia; G Natile; L G Marzilli
Journal:  Inorg Chem       Date:  2001-01-29       Impact factor: 5.165

4.  A 1H and 31P NMR study of cis-Pt(NH3)2[d(CpGpG)-N7(2),N7(3)]. The influence of a 5'-terminal cytosine, on the structure of the cis-Pt(NH3)2[d(GpG)-N7,N7] intrastrand cross-link.

Authors:  J H den Hartog; C Altona; G A van der Marel; J Reedijk
Journal:  Eur J Biochem       Date:  1985-03-01

5.  A rare example of three abundant conformers in one retro model of the cisplatin-DNA d(GpG) intrastrand cross link. Unambiguous evidence that guanine O6 to carrier amine ligand hydrogen bonding is not important. possible effect of the Lippard base pair step adjacent to the lesion on carrier ligand hydrogen bonding in DNA adducts.

Authors:  S T Sullivan; A Ciccarese; F P Fanizzi; L G Marzilli
Journal:  J Am Chem Soc       Date:  2001-09-26       Impact factor: 15.419

6.  Chirality-Controlling Chelate (CCC) Ligands in Analogues of Platinum Anticancer Agents. Influence of N9 Substituents of Guanine Derivatives (G) on the Distribution of Chiral Conformers of (CCC)PtG(2) with CCC = N,N'-Dimethyl-2,3-diaminobutane.

Authors:  Luigi G. Marzilli; Francesco P. Intini; Danita Kiser; Hing C. Wong; Susan O. Ano; Patricia A. Marzilli; Giovanni Natile
Journal:  Inorg Chem       Date:  1998-12-28       Impact factor: 5.165

7.  Circular dichroism spectra of the individual rotamers of [Pt(N,N-dmen)(GpG)]+ (N,N-dmen=N,N-dimethylethylenediamine) indicate that the base-base oscillator coupling is not the main source of ellipticity in cis-PtG2L2 head-to-head complexes.

Authors:  M A Elizondo-Riojas; V Bas; J Kozelka
Journal:  J Biol Inorg Chem       Date:  2000-02       Impact factor: 3.358

8.  X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))].

Authors:  S E Sherman; D Gibson; A H Wang; S J Lippard
Journal:  Science       Date:  1985-10-25       Impact factor: 47.728

9.  X-ray structure and circular dichroism of pure rotamers of bis[guanosine-5'-monophosphate(-1)](N,N,N',N'-tetramethylcyclohexyl-1,2-diamine)platinum(II) complexes that have R,R and S,S configurations at the asymmetric diamine.

Authors:  Michele Benedetti; Gabriella Tamasi; Renzo Cini; Giovanni Natile
Journal:  Chemistry       Date:  2003-12-15       Impact factor: 5.236

10.  cis-diamminedichloroplatinum(II) induced distortion of a single and double stranded deoxydecanucleosidenonaphosphate studied by nuclear magnetic resonance.

Authors:  J H den Hartog; C Altona; J H van Boom; G A van der Marel; C A Haasnoot; J Reedijk
Journal:  J Biomol Struct Dyn       Date:  1985-06
View more
  1 in total

1.  Complexes of dichloro(ethylenediamine)palladium(II) observed from aqueous solutions by electrospray mass spectrometry.

Authors:  Stephan B H Bach; Cassandra E Green; Linda I Nagore; Tiffanee G Sepeda; Grant N Merrill
Journal:  J Am Soc Mass Spectrom       Date:  2007-02-20       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.